AVBP (AVBP) Stock Price & Analysis
AVBP (AVBP) fell 0.26% to USD 30.95 as of September 8, 2026 at 04:14 UTC, according to Nexqual real-time market data.
AVBP last closed at USD 30.95; the session ranged USD 30.6–31.45 on volume of 182,982 shares. Market capitalization is —, with a 52-week range of USD 17–35.83 (NGM). Source: Nexqual, September 8, 2026 at 04:14 UTC.
Key Statistics (as of September 8, 2026 at 04:14 UTC)
| Price | USD 30.95 |
|---|---|
| Change | ▼ 0.26% (down) |
| Previous Close | USD 30.95 |
| Open | USD 30.95 |
| Day Range | USD 30.6 – 31.45 |
| 52-Week Range | USD 17 – 35.83 |
| Volume | 182,982 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (AVBP)
Nexqual's technical model rates AVBP "NEUTRAL" based on 3 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 04:14 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 57.17 (neutral) |
| vs SMA50 | Below (USD 31.33) |
| MACD | -0.04 (negative) |
Earnings (AVBP)
| Next Earnings Date | 2026-11-16 |
|---|---|
| EPS Estimate | USD -1.07 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -1.05 vs est -0.98 ▼ miss |
| 2026-03-31 | USD -0.96 vs est -0.89 ▼ miss |
| 2025-12-31 | USD -0.78 vs est -0.85 ▲ beat |
| 2025-09-30 | USD -0.83 vs est -0.78 ▼ miss |
Source: Nexqual, September 8, 2026 at 04:14 UTC.
Financials & Fundamentals (AVBP)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -53.25% |
| Debt / Equity | 0.1 |
| Current Ratio | 14.16 |
| Total Cash | $373.12M |
| Total Debt | $351,000 |
| Free Cash Flow | $-89.48M |
Source: Nexqual, September 8, 2026 at 04:14 UTC.
Financial Health Score (AVBP)
Nexqual rates AVBP's overall financial health "Mixed" across five dimensions, as of September 8, 2026 at 04:14 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $373M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$148M |
| Efficiency | Critical — ROE -53%, ROA -33.1% |
Ownership (AVBP)
| Insider Ownership | +1.54% |
|---|---|
| Institutional Ownership | +98.68% |
| Shares Outstanding | 49.31M |
| Float | 32.11M |
| Short % of Float | +17.70% |
Source: Nexqual, September 8, 2026 at 04:14 UTC.
From AVBP's Latest SEC 10-K Filing (filed 2026-03-05)
Source: SEC EDGAR 10-K. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CGON | CG Oncology, Inc. | USD 74.67 | ▲ 0.11% |
| BCAX | Bicara Therapeutics Inc. | USD 23.17 | ▼ 1.66% |
| ANRO | Alto Neuroscience, Inc. | USD 35.55 | ▼ 2.97% |
| RAPP | Rapport Therapeutics, Inc. | USD 45.77 | ▼ 6% |
| CTNM | Contineum Therapeutics, Inc. | USD 16.7 | ▼ 3.13% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 04:14 UTC. This page is informational and not investment advice.